GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Cyclically Adjusted Price-to-FCF

LIVN (LivaNova) Cyclically Adjusted Price-to-FCF : 56.59 (As of Oct. 09, 2024)


View and export this data going back to 1993. Start your Free Trial

What is LivaNova Cyclically Adjusted Price-to-FCF?

As of today (2024-10-09), LivaNova's current share price is $52.06. LivaNova's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was $0.92. LivaNova's Cyclically Adjusted Price-to-FCF for today is 56.59.

The historical rank and industry rank for LivaNova's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LIVN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 23.45   Med: 50.1   Max: 93.6
Current: 56.38

During the past years, LivaNova's highest Cyclically Adjusted Price-to-FCF was 93.60. The lowest was 23.45. And the median was 50.10.

LIVN's Cyclically Adjusted Price-to-FCF is ranked worse than
61.19% of 219 companies
in the Medical Devices & Instruments industry
Industry Median: 45.09 vs LIVN: 56.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

LivaNova's adjusted free cash flow per share data for the three months ended in Jun. 2024 was $0.572. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.92 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


LivaNova Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for LivaNova's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Cyclically Adjusted Price-to-FCF Chart

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.40 57.18 72.97 51.78 53.49

LivaNova Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.37 57.37 53.49 60.42 59.37

Competitive Comparison of LivaNova's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, LivaNova's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LivaNova's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where LivaNova's Cyclically Adjusted Price-to-FCF falls into.



LivaNova Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

LivaNova's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=52.06/0.92
=56.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LivaNova's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, LivaNova's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.572/133.0000*133.0000
=0.572

Current CPI (Jun. 2024) = 133.0000.

LivaNova Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201407 0.605 99.600 0.808
201410 0.839 100.100 1.115
201501 0.727 99.200 0.975
201504 0.570 99.900 0.759
201507 0.650 100.000 0.865
201510 1.088 100.300 1.443
201603 0.030 100.400 0.040
201606 -0.113 101.000 -0.149
201609 0.499 101.500 0.654
201612 0.640 102.200 0.833
201703 0.532 102.700 0.689
201706 -0.186 103.500 -0.239
201709 0.680 104.300 0.867
201712 0.155 105.000 0.196
201803 0.296 105.100 0.375
201806 0.421 105.900 0.529
201809 0.806 106.600 1.006
201812 0.165 107.100 0.205
201903 -0.078 107.000 -0.097
201906 -0.506 107.900 -0.624
201909 -1.757 108.400 -2.156
201912 -0.038 108.500 -0.047
202003 -2.351 108.600 -2.879
202006 -0.584 108.800 -0.714
202009 -0.038 109.200 -0.046
202012 0.625 109.400 0.760
202103 0.231 109.700 0.280
202106 0.393 111.400 0.469
202109 0.401 112.400 0.474
202112 0.486 114.700 0.564
202203 0.380 116.500 0.434
202206 -0.303 120.500 -0.334
202209 0.553 122.300 0.601
202212 0.179 125.300 0.190
202303 0.243 126.800 0.255
202306 -0.437 129.400 -0.449
202309 0.174 130.100 0.178
202312 0.753 130.500 0.767
202403 0.066 131.600 0.067
202406 0.572 133.000 0.572

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LivaNova  (NAS:LIVN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


LivaNova Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of LivaNova's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Executives
Francesco Bianchi director C/O LIVANOVA PLC, 5 MERCHANT SQUARE, LONDON X0 W2 1AY
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601